CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 896.90M |
| Revenue (ttm) | 76.20M |
| Net Income (ttm) | -20.37M |
| Shares Out | 217.69M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,123,199 |
| Open | 4.250 |
| Previous Close | 4.290 |
| Day's Range | 4.100 - 4.300 |
| 52-Week Range | 0.625 - 8.210 |
| Beta | 2.48 |
| Analysts | Strong Buy |
| Price Target | 12.10 (+193.69%) |
| Earnings Date | May 8, 2026 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $12.1, which is an increase of 193.69% from the latest price.
News
Why Is CytomX Therapeutics Stock Falling On Wednesday?
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has...
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 mont...
CytomX Therapeutics Earnings Call Transcript: Q4 2025
Phase I data for Varseta-M in late-line CRC show strong efficacy (up to 32% ORR, 7.1 months PFS) and improved safety with dual prophylaxis, supporting rapid advancement to registrational studies and expansion into earlier CRC lines and other tumors.
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - ...
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi...
CytomX Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Masked ADC technology is showing promising early results in late-line metastatic CRC, with a 28% response rate and manageable safety profile. Dose expansion and combination studies are underway, with a registrational study targeted for 2027.
CytomX Therapeutics to Present at Upcoming February Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
EMERYVILLE, Calif.--(BUSINESS WIRE)--Wareham Development today confirmed a full floor lease has been signed with CytomX Therapeutics at 5959 Horton Street (EmeryStation West).
CytomX Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a robust oncology pipeline with Vaseta M showing strong efficacy and safety in late-line colorectal cancer and plans for expansion into earlier lines and other tumors. CX801 demonstrated promising immune activation in melanoma, with combination data expected by end of 2026.
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to...
CytomX Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Probody masking technology showed strong clinical validation in 2025, with CX-2051 achieving notable efficacy and safety in late-stage colorectal cancer and expansion plans underway. CX801 and CX908 advance the pipeline, supported by robust cash reserves and active partnerships.
CytomX Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase 1 data for a masked anti-EpCAM ADC in late-stage colorectal cancer showed a 28% response rate and 94% disease control, with expansion to 100 patients and a major update planned for Q1 2026. Additional studies in other solid tumors and a masked interferon alpha program are advancing.
CytomX Therapeutics to Present at Upcoming December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
CytomX Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted significant progress for the Probody platform, with CX-2051 showing strong efficacy and safety in late-line CRC. Enrollment is expanding to support a robust phase one data package for FDA discussions in 2026, backed by solid financials.
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean M...
CytomX Therapeutics Earnings Call Transcript: Q3 2025
Lead candidate CX-2051 showed strong efficacy and safety in late-line CRC, with a 28% response rate and 5.8-month PFS, while CX-801 advanced in melanoma. Cash reserves of $143.6M support operations into 2027, with key data updates and new studies planned for 2026.
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 s...
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wil...
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
Leadership team addition to drive strategic long-term value creation and partnering strategy Leadership team addition to drive strategic long-term value creation and partnering strategy